RxDoctor Payments DataLook up a doctor →

Matthias Holdhoff, MD

Medical Oncology · Baltimore, MDNPI 1386709046

Payments from drug & device makers

$2,113,312in general payments, 2019–2025

Across 250 payments — averaging $8453.25 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Servier Bioinnovation$1.7M
  • E.r. Squibb & Sons, L.L.C.$262K
  • Servier Pharmaceuticals LLC$74K
  • Merck$41K
  • Agios Pharmaceuticals, Inc.$25K
  • Novartis$6K
  • plus $6K from 7 others
$4,643in research payments, 2019–2025

Across 9 payments — averaging $515.88 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Servier Affaires Medicales$5K

General payments by program year

19
21
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

How this compares

$2,113,312 in reported general payments places this provider in the 80th percentile of 180 medical oncology providers in Maryland.

See all medical oncology providers in Maryland

Medicare billing

Part B allowed, 2024
$47,577
Medicare patients
128
Services billed
484

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other medical oncology in Baltimore

See the full list for Maryland

Where these figures come from

Is this you, or does something look wrong? →